Cerus Announces Positive Phase III REDeS Study Results and Strategic Shift to Kit-Based Model
Cerus (CERS) reported significant progress during its third-quarter 2026 earnings call, highlighted by the successful completion of the Phase III REDeS study. The study met primary efficacy and safety endpoints for red blood cell pathogen reduction technology, opening a massive new market opportunity for the company's transfusion technologies. Strategically, Cerus is transitioning its INTERCEPT Fibrinogen Complex (ISC) business from finished therapeutic sales to a higher-margin kit distribution model. This shift, supported by a nationwide partnership with Blood Centers of America (BCA), aims to boost gross margins and accelerate hospital adoption without increasing internal sales costs. The company also reported positive cash flow from operations of $3 million and noted that international placements of the INT200 Illuminator device are exceeding expectations. Management expressed confidence in achieving GAAP profitability as they expand their core franchises.
Tickers: $CERS
Topics: Blood Safety Technology Medical Devices Phase III Clinical Trial Q3 Earnings